Document is current
Any future updates will be listed below
-
Authors
Cicone, Francesco http://orcid.org/0000-0003-4664-1965
Gnesin, Silvano
Denoël, Thibaut
Stora, Thierry
van der Meulen, Nicholas P.
Müller, Cristina
Vermeulen, Christiaan http://orcid.org/0000-0002-6723-8983
Benešová, Martina
Köster, Ulli
Johnston, Karl
Amato, Ernesto
Auditore, Lucrezia
Coukos, George
Stabin, Michael
Schaefer, Niklaus
Viertl, David
Prior, John O. http://orcid.org/0000-0003-1429-1374
-
Funding
Funding for this research was provided by:
Horizon 2020 (642889 MEDICIS-PROMED, 654002 ENSAR2)
- License Information
-
More Information
Article History
Received: 8 March 2019
Accepted: 28 May 2019
First Online: 11 June 2019
Ethics approval and consent to participate
: All animal experiments in the present study were conducted according to the Swiss federal law on animal experimentation under the authorization number VD-2993. The present study does not include any experiment performed on human subjects.
: Not applicable. The present study does not contain any individual person’s data in any form.
: MS receives royalties from sales of the OLINDA/EXM software. GC has received grants, research support or is co-investigator in clinical trials by BMS, Celgene, Boehringer Ingelheim, Roche, Iovance, and Kite. GC has received honoraria for consultations or presentations by Roche, Genentech, BMS, AstraZeneca, Sanofi-Aventis, Nextcure, and GeneosTx. GC holds patents around TEM1 antibodies. GC is receiving royalties from Penn regarding technology licensed to Novartis.
